DONALD J. ENRIGHT. During his 15 years as a litigator and trial lawyer, Mr. Enright has handled matters in the fields of securities, commodities, consumer fraud and commercial litigation, with a particular focus on shareholder M&A and securities fraud class action litigation. He has a track record of achieving victories in federal trials and appeals, including Nathenson v. Zonagen, Inc., 267 F. 3d 400, 413 (5th Cir. 2001); SEC v. Butler, 2005 U.S. Dist. LEXIS 7194 (W.D. Pa. April 18, 2005); and Belizan v. Hershon, 434 F. 3d 579 (D.C. Cir. 2006). Indeed, Mr. Enright has played a lead role in numerous securities class actions from inception to conclusion, including multi-million dollar settlements in cases involving Allied Irish Banks, PLC, Iridium World Communications, Ltd., En Pointe Technologies, Inc., PriceSmart, Inc., Polk Audio, Inc., Meade Instruments Corp., Xicor, Inc., Streamlogic Corp., Interbank Funding Corp., Riggs National Corp., UTStarcom, Inc., and Manugistics Group, Inc. Mr. Enright also recently won a preliminary injunction, enjoining a tender offer merger, while serving as co-lead counsel in the matter of In re: Portec Rail Products, Inc. Shareholder Litigation.
Mr. Enright is a 1993 cum laude graduate of Drew University, where he earned a Bachelor of Arts in Political Science and Economics, and a 1996 graduate of the George Washington University Law School, where he received his Juris Doctor. He was a Member Editor of The George Washington University Journal of International Law and Economics from 1994 to 1996, and clerked for the House Judiciary Committee in 1994. He is a member of the Bars of the District of Columbia, Maryland, and New Jersey, and is admitted to practice before several United States District Courts and Circuit Courts. Mr. Enright practices in the firm's Washington, DC office, and has been named as one of Washington's "Top Lawyers" by Washingtonian Magazine. His published securities litigation-related articles include:
• "SEC Enforcement Actions and Investigations in Private and Public Offerings," Securities: Public and Private Offerings, Second Edition, West Publishing 2007.
• "Dura Pharmaceuticals: Loss Causation Redefined or Merely Clarified?", J. Tax'n & Reg. Fin. Inst., September/October 2007, at 5.